Now FDA approved for use in the U.S. and available from your veterinary distributor, Tildren
®
(tiludronate
disodium) controls clinical signs associated with navicular syndrome in horses. Tildren works at the areas of
active bone resorption, restoring balance to the process of bone remodeling.
NOW AVAILABLE IN THE U.S.
Over 250,000 doses administered worldwide in the last 12 years.
©2015 Ceva Animal Health, LLC. Lenexa, KS 66215 TILDREN is a registered trademark of Ceva Santé Animale, France.
Do not use in horses with impaired renal function or with a history of renal disease. NSAIDs should not be used
concurrently with TILDREN. Concurrent use of NSAIDs with TILDREN may increase the risk of renal toxicity and
acute renal failure. Horses should be observed closely for 4 hours post-infusion for the development of clinical signs
consistent with colic or other adverse reactions. Caution should be used when administering TILDREN to horses
with conditions affecting mineral or electrolyte homeostasis (e.g. HYPP, hypocalcemia) and conditions which may be
exacerbated by hypocalcemia (e.g. cardiac disease). The safe use of TILDREN has not been evaluated in horses less
than 4 years of age, in pregnant or lactating mares, or in breeding horses.
Contact your local distributor or Ceva Animal Health representative for more information.
TILDREN.COM/US